NanoPhoria
Preclinical-stage biotechnology company developing inhaled, nano‑in‑micro pulmonary delivery technology built on inorganic calcium phosphate nanoparticles to enable tissue-directed therapeutics for cardiovascular disease, with a primary focus on heart failure with reduced ejection fraction (HFrEF).
Industries
Nr. of Employees
small (1-50)
Products
Inhaled Nano‑in‑Micro delivery platform
A platform technology for aerosol administration of therapeutic payloads using nano‑in‑micro architectures built on inorganic calcium phosphate nanoparticles.
NP-MP1
NP-MP1 is an investigational three-level dry powder formulation designed for inhaled delivery to treat Heart Failure with reduced Ejection Fraction (HFrEF) by regulating dysfunctional L-type calcium channels in cardiomyocytes.
Nano-in-Micro delivery platform
A proprietary delivery platform built on inorganic Calcium Phosphate nanoparticles designed for inhalation and other administration routes.
Inhaled Nano‑in‑Micro delivery platform
A platform technology for aerosol administration of therapeutic payloads using nano‑in‑micro architectures built on inorganic calcium phosphate nanoparticles.
NP-MP1
NP-MP1 is an investigational three-level dry powder formulation designed for inhaled delivery to treat Heart Failure with reduced Ejection Fraction (HFrEF) by regulating dysfunctional L-type calcium channels in cardiomyocytes.
Nano-in-Micro delivery platform
A proprietary delivery platform built on inorganic Calcium Phosphate nanoparticles designed for inhalation and other administration routes.
Services
Development programs focused on inhaled therapeutic candidates for heart failure with reduced ejection fraction, from formulation to preclinical evaluation.
Development programs focused on inhaled therapeutic candidates for heart failure with reduced ejection fraction, from formulation to preclinical evaluation.
Expertise Areas
- Inhalation drug delivery
- Nanoparticle formulation and materials (calcium phosphate)
- Preclinical and translational development
- Cardiovascular therapeutics (HFrEF)
Key Technologies
- Nano‑in‑micro inhalation formulations
- Inorganic calcium phosphate nanoparticles
- Pulmonary aerosolization and delivery
- Formulation engineering
News & Updates
Received second-place prize in INNLIFES’ “I Protagonisti Dell’innovazione 2026” contest.
Scientific publication referenced on the site related to heart failure outcomes.
Received second-place prize in INNLIFES’ “I Protagonisti Dell’innovazione 2026” contest.
Scientific publication referenced on the site related to heart failure outcomes.